A phase II, multicenter, single-arm study of eribulin mesilate as first-line therapy for HER2-negative locally advanced or metastatic breast cancer. This is an ASCO Meeting Abstract from the 2015 ASCO ...
Ayres, P. J., Barlow, J., Garrod, O., Kellie, A. E., Tait, J. F., Tait, S. A. S., and Walker, G., in International Symposium on Aldosterone, edit. by Muller and O ...
TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback